Antithrombotic activity of Bay u3405, a thromboxane A2-antagonist, in patients with Dacron aortic grafts: a random controlled clinical trial. 
Twelve patients with Dacron aortic grafts participated in a placebo controlled, crossover trial to investigate the effect of Bay u3405, a thromboxane A2 receptor antagonist, on graft thrombogenicity.  During each treatment period (seven days, Bay u3405 or placebo), 111In-platelet survival and platelet deposition on the grafts were measured daily by gamma-camera imaging and blood radioactivity analysis.  Bay u3405 substantially reduced the deposition of platelets and the thrombogenic index, while platelet survival remained unchanged.  The ex vivo platelet aggregation response to ADP and epinephrine was significantly inhibited.  The bleeding time increased slightly but not to any clinically relevant extent, and no adverse side effects were recorded.  Bay u3405 seems to be a safe and effective drug for the inhibition of platelet deposition on aortic Dacron grafts.  The use of quantitative imaging techniques is also more sensitive than the measurement of platelet survival for the assessment of antiplatelet drug efficacy in patients with aortic grafts.